
Microbiology 101 for Infection Preventionists

Rebecca Battjes, MPH, CIC, FAPIC Senior Clinical Advisor, Diversey







NHHHHHHHHH

Disclosure

Rebecca is employed by Diversey—A Solenis Company. Her expenses to attend this presentation (travel, accommodation, and salary) are paid by this company. Diversey has had no input into this presentation from a commercial interest.



Table of contents




If I can learn micro, anyone can!

- Bachelor's degrees in English & Spanish literature
- Zero microbiology coursework in college, including MPH program.
- I took APIC courses, learned from my colleagues on the job & used Google (a lot!).








What Are Microorganisms?

- Microbes have existed for over **3 billion years!**
- Pathogens are microbes that cause disease ("pathogenic")
 - BUT not all microbes are pathogens
- Categorized according to biological taxonomy
 Example: bacteria are known by genus
 (*Escherichia*) and species (*coli*)
- Human body has:

- 10 trillion human cells
- 100 trillion microbes



Biological classification:

5 Types of Microbes





Viruses



Fungi



Parasites

Prions

MICROORGANISMS SIZE COMPARISON

Bacteria

Characteristics

- Single cell
- Most are harmless (normal flora)
- Different growth characteristics
- Named by genus and species

How to identify

- Visible under a light microscope- gram stain
- Culture
- Other specialized laboratory tests

Examples of Pathogens

- Methicillin-resistant Staphylococcus aureus
- Streptococcus pneumoniae
- Pseudomonas aeruginosa

Treatment

• Antibiotics



Viruses

Characteristics

- Acellular
- Only able to replicate in a host's cell
- 10,000 times smaller than bacteria

How to identify

- Culture- grown inside cells
- NOT visible under a light microscope
- Identified using specific stains and methods and other specialized laboratory tests


Examples of Pathogens


- Influenza
- Varicella (chickenpox)
- Covid-19

Treatment

Antivirals or supportive therapy







Can you kill a virus?



Characteristics

- Unicellular and multicellular
- Most are not dangerous (yeast, mold, mushrooms)
- Some can be harmful to health

How to identify


 Culture and special stains and other specialized laboratory tests

Examples of Pathogens

- Candida auris
- Aspergillus fumigatus

Treatment

Antifungals



Parasites

Characteristics

- Live on or in a host and gets nutrients at the expense of the host
- Unicellular or multicellular

How to identify

Light microscopy, blood tests and other specialized laboratory tests


Examples of Pathogens

- Malaria (Plasmodium)
- Cryptosporidium
- Giardia

Treatment

• Antiparasitic





Scabies

Prions

Characteristics

- Pathogenic agent able to induce abnormal folding of specific normal cellular proteins
- Causes Prion disease or transmissible spongiform encephalopathies (TSEs)- rare progressive neurogenerative disorders
- Affects both humans and animals

How to identify

 Brain biopsy or autopsy and other specialized laboratory tests (typically a sent to a reference laboratory!)


Examples of Pathogens

Creutzfeldt-Jakob Disease (CJD)

Treatment

Supportive treatment





Effect of Disinfectants on Microorganisms

| Organism | Туре | Examples |
|-----------------------------|----------|--|
| Bacterial Spores | Spore | Bacillus anthracis, C. difficile |
| Mycobacteria | Bacteria | M. tuberculosis, M. Terrae (Can) |
| Small non-enveloped virus | Virus | Poliovirus, Norovirus, Hep A |
| Fungal spores | Fungus | Aspergillus, Penicillium, Trichophyton |
| Gram negative bacteria | Bacteria | E. coli, Klebsiella including CRE , Pseudomonas, Acinetobacter |
| Fungi (Vegetative) | Fungus | Candida species |
| Large Virus (non-enveloped) | Virus | Adenovirus, Rotavirus |
| Gram positive bacteria | Bacteria | Staphylococcus including MRSA Enterococcus including VRE |
| Virus (enveloped) | Virus | HIV, HBV, HCV, Influenza, Mpox |

^Resistant * Sensitive

S*

R^

Adapted from Rutala & Weber. ICHE 2014;35(7):862; McDonnell & Burke, J Hosp Infect 2011;78(3):163-70.

ANTIMICROBIAL RESISTANCE

DISINFECTANT RESISTANCE

Rozman U, Pušnik M, Kmetec S, Duh D, Šostar Turk S. Reduced Susceptibility and Increased Resistance of Bacteria against Disinfectants: A Systematic Review. Microorganisms. 2021 Dec 10;9(12):2550. doi: 10.3390/microorganisms9122550. PMID: 34946151; PMCID: PMC8706950.

Examples of exceptions to the hierarchy of disinfectants





Human papillomavirus (HPV)

https://www.cdc.gov/mmwr/pdf/rr/rr6305.pdf

Candida auris




Microbiology Testing & Reporting

Gram Stain - Bacteria

After the provider's initial assessment, the gram stain is going to be one of the the first clues as to what is going on with the patient.

Gram Positive Result

Indicates the bacteria has a thick cell wall with proteins (peptidoglycan). Gram positive cells appear **purple**.



Gram Negative Result

Indicates the bacteria does not have an extra layer in the cell wall. Gram negative cells appear **pink/red**.




Bacterial Cellular Morphologies

SHAPE:

Coccus- spherical shape Bacillus- rod shaped Coccobacillus- intermediate shape between coccus and bacillus

ARRANGEMENT:

Chains Clusters Diplo (arrangements of 2)




Examples: Organism & Gram Stain GRAM POSITIVES (PURPLE!)




Bacillus anthracis gram positive bacilli

https://phil.cdc.gov/details.aspx? pid=2226



Streptococcus pneumoniae - gram positive cocci in pairs and short chains

https://www.merckmanuals.com/enca/professional/multimedia/image/gram-stainstreptococcus-pneumoniae-



Staphylococcus aureus gram positive cocci in clusters

> https://en.wikipedia.org/wiki/Staph ylococcus_aureus






Acinetobacter baumanii short gram-negative bacilli

> https://phil.cdc.gov/Details.aspx? pid=1260



Neisseria meningitidis – gram-negative diplococci

https://phil.cdc.gov/details.asp x?pid=6423



Pseudomonas aeruginosa - gram-negative bacilli


https://textbookofbacteriology.net/pseudo monas.html

POP QUIZ: WHICH GRAM STAIN RESULTS REQUIRES IMMEDIATE IP ATTENTION & ACTION?



Acinetobacter baumanii short gram-negative bacilli

> https://phil.cdc.gov/Details.aspx? pid=1260



Neisseria meningitidis – gram-negative diplococci

> https://phil.cdc.gov/details.asp x?pid=6423




Pseudomonas aeruginosa - gram-negative bacilli

https://textbookofbacteriology.net/pseudo monas.html


Other Common Stains

Acid-fast stain (Ziehl-Neelsen stain)- determines if a sample of tissue, blood, or other body substance is infected with tuberculosis (TB) and other illnesses.


Capsule stain- India ink is used for easy visualization of the capsule of the yeast Cryptococcus neoformans. The particles of ink pigment do not enter the capsule that surrounds the spherical yeast cell, resulting in a "halo" around the cells.




https://en.wikipedia.org/wiki/Ziehl%E2%80%93Neelsen_stain



https://en.wikipedia.org/wiki/Cryptococcus_neoformans



When the micro lab calls with a positive on an active inpatient AFB result, what do you do first?



Positive AFB **PLUS** suspicion of pulmonary TB requires immediate placement into AIIR.

Contact ID/med director & give employee health a heads up. BUT DO NOT SEND AN EXPOSURE YET! You do not have organism identification.

Reassure staff that IP will follow up if MTB is identified. You do not need to stay late after ensuring isolation is active.

Bacterial Identification: Culture

- Bacteria are grown in a petri dish using special growth media
- Time it takes to grow is organism dependent- some take hours and others take days
- May be able to identify a bacteria to genus and species based on culture alone
- Cultures can be done manually but advancements have led to automation



Traditional Bacterial Culture



Microorganism Identification: MALDITOF

Matrix-Assisted Laser Desorption Ionization Time of Flight (MALDITOF)

Laboratory automation providing faster and more accurate results than conventional identification methods for the identification and antimicrobial susceptibility testing of most bacterial and fungal clinical isolates.

Decreases the turnaround time for the provision of definitive identification and susceptibility results to clinicians.

Understanding MALDI-TOF Mass Spectrometry




Figure 1. Depiction of internal MALDI-TOF mass spectrometry process


https://www.beckmancoulter.com/products/microbiology/maldi-tof-mass-spectrometry

Microorganism Identification: Polymerase Chain Reaction (PCR)

Diagnosis of infectious diseases has been revolutionized by the development of molecular techniques, mainly with the applications of polymerase chain reaction (PCR).

How does it work?

- The sample is heated so the DNA denatures
- The DNA separates into two pieces of single-stranded DNA
- An enzyme (Taq polymerase) synthesizes two new strands of DNA (using the original strands as templates)
- Denaturing and synthesis occurs multiple times leading to the more than a billion copies of the original DNA segment
- This can be completed in a few hours using a machine called a thermocycler which alters the temperature of the reaction every few minutes to allow DNA denaturing and synthesis.



https://www.intechopen.com/chapters/66383 https://www.genome.gov/about-genomics/fact-sheets/Polymerase-Chain-Reaction-Fact- Sheet#:~:text=How%20does%20PCR%20work%3F,the%20original%20strands%20as%20templates.

Microorganism Identification: Polymerase Chain Reaction (PCR)

Advantages

- Effectively developed for a wide range of microorganisms
- High sensitivity and specificity
- Faster turnaround times
- Good for organisms that cannot be grown in vitro, or when where existing culture techniques are insensitive and/or need prolonged incubation times




https://www.intechopen.com/chapters/66383

https://www.genome.gov/about-genomics/fact-sheets/Polymerase-Chain-Reaction-Fact- Sheet#:~:text=How%20does%20PCR%20work%3F,the%20original%20strands%20as%20templates.

Pulsed-Field Gel Electorphoresis (PFGE) (DNA Fingerprinting)

- Laboratories use high-tech equipment to make the DNA fingerprints.
- Each type of bacteria has unique DNA which makes up a pattern of bands called a fingerprint.
- Bacterial fingerprints are found by cutting the bacteria's DNA into tiny pieces and then placing them on an agarose gel.
- Electricity is sent through the gel and the DNA pieces separate.
- Small pieces of DNA get carried farther down the gel than bigger pieces. This process creates a banding pattern or "fingerprint".
- PFGE is useful for assisting epidemiological investigations of illnesses caused by a common-source of pathogen such as Escherichia coli O157 : H7 in food poisoning or MRSA causing an outbreak in health care.




Whole Genome Sequencing (WGS)


- All organisms (bacteria, vegetable, mammal) have a unique genome composed of nucleotide bases (A, T, C, and G)
- If you know the sequence of the bases in an organism, you have identified its unique DNA fingerprint, or pattern.
- Determining the order of bases is called sequencing.
- WGS is a laboratory procedure that determines the order of bases in the genome of an organism in one process.


* Gives an exact DNA profile of an organism

https://www.cdc.gov/pulsenet/pathogens/wgs.html



Typically performed by state lab & can help identify the source of an outbreak!





If reference labs are used, know who to contact for these questions!

Antibiotic Susceptibility Testing Intrinsic or Acquired Resistance?

Intrinsic Resistance: Resistance mechanism on original bacterial chromosome

Acquired Resistance: Changes to original genome - bacteria becomes resistant

Mutations: original genes altered but no new genes acquired.

Transferable: new genes acquired through plasmids or transposable elements.

*Transferable resistance is of IC concern because can pass to different bacteria & can spread person to person.



Michener Institute, Toronto

Example: Gram Negative Bacteria with Intrinsic Resistance

MIML240

APPENDIX B- LIST OF ORGANISMS WITH INTRINSIC RESISTANCE

GRAM NEGATIVE BACILLI

| Antibiotic Organism | Ampicillin | Aminoglycoside | Cefazolin, Cefalothin | Cefuroxime | Cefotaxime/ Ceftraixone | Nitrofurantoin | SXT |
|---|------------|----------------|--------------------------|------------|----------------------------|----------------|-----|
| Acinetobacter <u>baumanii,</u> calcoaceticus | R | | | | | | |
| Burkholderia cepacia complex | R | R | | | R | | |
| Citrobacter freundii | R | | R | R | | | |
| Citrobacter koseri | R | | | | | | |
| Enterobacter aerogenes | R | | R | R | | | |
| Enterobacter cloacae complex | R | | R | R | | | |
| Hafnia alvei | R | | R | | | | |
| Klebsiella pneumoniae | R | | | | | | |
| Morganella morganu | R | | R | ĸ | | R | |
| Proteus mirabilis | 2.4.3 | | | | | R | |
| Proteus penneri | R | | R | R | | R | |
| Proteus vulgaris | R | | R | R | | R | |
| Providencia rettgeri | R | | R | | | R | |
| Providencia stuartii | R | | R | | | R | |
| Pseudomonas aeruginesa | R | | | | R | R | R |
| Serratia marcescens | R | | R | R | | R | |
| Stenotrophomonas maltophilia | R | R | - | | R | | |
| Yersinia enterocolítica | R | | R | | | | |

Sample Microbiology Reports...





| () PCR, SHL Respiratory Panel | Orden 4004 | | | | |
|--|---|--|--|--|--|
| Status: Final result Visible to patient: Yes (not seen) Next | appt: Today at 17:00 in Nephrology (SHG HEMODIALYSIS, GENERIC NURSE) | | | | |
| Specimen Information: Nasopharym; Swab | | | | | |
| 2 Result Notes 1 Patient Communication | í - | | | | |
| Component Ref Range & Units | | | | | |
| Adenovirus | Not Differred | | | | |
| 図 covib19 | COVID-19 virus DETECTED by real-time PCR. (| | | | |
| 20 Rhino/Enterovirus | Not Detected | | | | |
| 🔄 influenza A | Not Detected | | | | |
| 🔯 Influenza A H1 (pdm09) subtype | Not Detected | | | | |
| 🔄 Influenza A H3 subtype | Not Detected | | | | |
| 📴 influenza B | Not Detected | | | | |
| Seasonal Human coronavirus (229E/OC43/NL63/HKUT | Not Detected | | | | |
| D MPV | Not Detected | | | | |
| Paraninfluenza Virus Types 1,2,3,4 | Not Detected | | | | |
| 図 RSV | Not Detected | | | | |
| Narrative | | | | | |
| Note: | | | | | |
| This is a validated Laboratory-developed rea | | | | | |
| The results should be interpreted based on t | he clinical context of the patient. | | | | |
| Health Unit Notified. | | | | | |
| Epecimen Collected: 30/10/23 22:29 | Last Reculted: 01/11/23 3:40 | | | | |
| | 🔊 Order Details 🔍 View Encounter 🛛 Lab and Collection Details 🛤 Routing 🥯 Result Hi | | | | |
| | View All Conversations on this Endo | | | | |



| Specimen Monnation: Blood, Central Like O Result Notes: Culture Visition of the Cherohold for National Scherohold for Scherohold for a susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indined + % Kultolet processing of the sense date for susceptibilities. Indine to Attende for susceptibility Gram result for strate for susceptibility Susceptibility Kultolet processing Gentaminent Cathianone (+SS supplit Scieptible (Cathianone (+SS supplit Scieptible Cathianone (+SS supplit Scieptible Cathianone (+SS supplit Scieptible Cathianone (+SS supplit Scieptible (Cathianone (+SS supplit Scieptible (+SS supplit) Susceptibility | Culture, Blood Status: Edited Result - FINAL Visible to patient | Order: 3881701 No (inaccessible in MyChart) Next app: 05/01/2024 at 07:15 in Nepheology (SHG SATELLITE DIALYSIS NURSE) |
|---|--|---|
| Culture volume v | | |
| Infer to 1330-13300000 college) 0 in the base date for succeptibilities. Number 4 = Kiskiski preumonie 1 ***This is an appended specif, These meatics have been appended to a previously final verified seport.*** File 15 at appended specif, These meatics have been appended to a previously final verified seport.*** File 15 at a previously at appended specif. File 15 at the detection 5.03 hours Gram Stain Secretibility Related from second Ampiolin 0.10 upper 1 Cataoln 4.00 upper 1 Susceptibility Secretibility Secretibility < | 0 Result Notes | |
| Susceptibility Klebsiells preumoniae Mic Ampicilin > 16 ug/ml Ampicilin > 16 ug/ml Cefazoin 4 ug/ml Cefazoin 4 ug/ml Cefazoin < 40.5 ug/ml Cefazoin < =0.125 ug/ml Susceptibility Cefazoin <=0.125 ug/ml Susceptible Gentamicin <=2 ug/ml Tohramycin <=2 ug/ml Tohramycin <=2 ug/ml Susceptible Tohramycin <=2 ug/ml Susceptible Tohramycin <=2 ug/ml Susceptible Tohramycin <=2 ug/ml Susceptible Supremer Collected: 10/09/23 13:54 Lust Resulted: 14/09/23 646 | Culture | Nafer to 1998-18500040 collected on the same date for susceptibilities. Holated +> Klabsiella pneumoniae 1 ****This is an appended report. These results have been appended to a previously final verified report.*** isolated from service and ansarobic blood culture bottles. Time to Detection 5.00 hourm |
| Susceptibility Klebslells pneumoviae Klebslells pneumoviae Ampicillin * 16 ug/mt Kesistant Cefazoln 4 ug/mt Intermediate Cefbiasone <=0.5 ug/mt Susceptible Ciprofioxacin <=0.125 ug/mt Susceptible Gentamicin <=2 ug/mt Susceptible Gentamicin <=2 ug/mt Susceptible Tohramyrioin <=0.5/9.5 u. Susceptible uperumer Collected: 10/09/23 13:54 Lest Resulted: 14/08/23 8-46 | Gram Stain | Gram negative bacili seen |
| Niebiella pneumoniae Mapicilin > 16 ug/mt Cefazoln 4 ug/mt Ceftosixone <=0.5 ug/mt | Susceptibility | |
| Cefazoln 4 ugmini Intermediate Ceftziasone <=0.5 ug/ml | | |
| Ceftriasone <=0.5 ug/ml | Ampicillin | » 16 uq/ml Resistant |
| Ciprofloxacin <=0.125 ug/ml | Cefazolin | 4 ug/ml Intermediate |
| Gertamicin • • • 2 ug/ml Susceptible Tobramycin • • • 2 ug/ml Susceptible Trimethoprim • Sulfamethoxabole • • • 0.5/9.5 u Susceptible pecimen Collected: 10/09/23 13:54 Lest Resulted: 14/09/23 8:46 El Coder Details * View Encounter * Lab and Collection Details ** Routing ** Result History • Result for | Ceftriaxone | <=0.5 ug/ml Susceptible |
| Tobranycin <=2 ug/ml | Ciprofloxacin | <=0.125 ug/ml Suicephble |
| Trimethoprim + Sulfamethoxazole <=0.5/9.5 uSusceptible pecimen Collected: 10/09/23 13:54 ECoder Details View Encounter View | Gentamicin | <=2 ug/ml Susceptible |
| pecimen Collected: 10/09/23 13:54 Di Order Details 💜 View Encounter 🕷 Lab and Collection Details 🛱 Routing. 🧐 Result History - Result Ed | Tobramycin | <=2 ug/ml Susceptible |
| 🗐 Order Details 🔮 View Encounter 🕷 Lab and Collection Details 😂 Routing 😕 Result History - Result Ed | Trimeshoprim + Sulfamethoxazole | |
| View All Conversitions on the Encou | Ipecimen Collected: 10/09/23 13:54 | 🔊 Order Details 🔍 View Encounter 🕷 Leb and Collection Details 🛤 Routing 🧐 Result History - Result Edite |
| | | View All Conversitions on this Encluring |
| | | Piloz. |

| ᡗ Culture, Urine | | | | Order: 3950103 |
|--|--|---|-----------------------|----------------|
| Status: Final result Visible to patient: Yes (not se | en) Next appt: None | | | |
| Specimen Information: Urine, Midstream | | | | |
| 0 Result Notes | | | | |
| Culture >10 | 0 X 10E6 CFU/L <> Kle | bsiella variicola 📍 | | |
| | 0 X 10E6 CFU/L <> Ent | erococcus faecalis ! | | |
| Susceptibility | | | | |
| | 121-1 | osiella variicola | Enterococcus faecalis | |
| | Kiet | MIC | DISK DIFFUSION | |
| Ampicillin | 8 ug/ml | MIC | | |
| Ampicillin Cefazolin | 8 ug/ml | MIC | DISK DIFFUSION | |
| | 8 ug/ml | MIC Resistant Susceptible | DISK DIFFUSION | |
| Cefazolin | 8 ug/ml <=2 ug/ml <=0.125 ug/ml | MIC Resistant Susceptible | DISK DIFFUSION | |
| Cefazolin Ciprofloxacin | 8 ug/ml <=2 ug/ml <=0.125 ug/ml <=2 ug/ml | MIC Resistant Susceptible Susceptible | DISK DIFFUSION | |
| Cefazolin Ciprofloxacin Gentamicin | 8 ug/ml <=2 ug/ml <=0.125 ug/ml <=2 ug/ml <=32 ug/ml | MIC Resistant Susceptible Susceptible Susceptible | DISK DIFFUSION | |

Specimen Collected: 08/10/23 13:45

Last Resulted: 13/10/23 12:56

🖻 Order Details 🔮 View Encounter 🔰 Lab and Collection Details 🖾 Routing 🧐 Result History

View All Conversations on this Encounter



| Status Final result Visible to patient: No (inaccessible in MyChart). Next appt Nome Specimien Information: Elbow, Left, Swab O Result Notes Culture | Chde:: 41384700 | | | | ous | ① Culture, Wound, Deep/Subcutane |
|---|--|--|---|--|---------------------|---|
| 0 Result Notes Culture Heavy Growth <> Staphylococcus aureus ! Insomptikility comment: Bisphylococcus Group A ! Heavy Growth <> Staphylococcus Group A ! Scientify sensitive to Formillin. Scart Growth <> Mary Pus cells seen Many Gram positive cocci seen Susceptibility Clindamych 0.25 ug/ml Susceptible 1 Clindamych 0.25 ug/ml Susceptible (| | | | Next appt: None | essible in MyChart) | |
| Culture Heavy Growth <> Staphylococcus aureus ! | | | | | | Specimen information: Elbow, Left; Swab |
| Susceptibility comment: Stephylocol of that test susceptible to coacillin are also susceptible to closecillin and Heavy Growth <> Stephylocol of that test susceptible to coacillin are also susceptible to closecillin are test susceptible to closecillin are also also also also also also also also | | | | | | 0 Result Notes |
| Scart Growth Mixed Coliforms & skin flura † Gram Stain Many Pus cells seen Many Gram positive cocci seen Susceptibility Staphylococcus aureus Mac Clindamycin O,25 ug/ml Susceptible Clindamycin O,25 ug/ml Susceptible Trimethoprim + Sulfamethoxazole cv0.5/9.5 u. Susceptible | efacolin, | lin are also susceptible to closerillin and cefacolin | chylocolci that test susceptible to opacil pA1 | Furgerptibility comment: Step/ eavy Growth <= Streptococcus Group | | Culture |
| Susceptibility Staphylococcus aureus Mic Clindamycin 0.25 ug/ml Susceptible 1 Erythromycin >4 ug/ml Resistant Okacilin 0.5 ug/ml Susceptible Trimethoprim + Sulfamethosazole «=0.5/9.5 u | | | | | Sec | |
| Susceptibility Staphylococcus aureus MAC Clindamycin 0.25 ug/ml Erythromycin >4 ug/ml Oxacilin 0.5 ug/ml Disacilin 0.5 ug/ml Trimethoprim + Sulfamethosazole <=0.5/9.5 u. | | | | | | Gram Stain |
| Staphylococcus aureus Mic Clindamycin 0.35 ug/ml Erythromycin >4 ug/ml Resistant Ohacilin 0.5 ug/ml Trimethoprim + Sulfamethosazole «=0.5/9.5 u Susceptible | | | | | | Susceptibility |
| Ersthnomycin >4 ug/mi Resistant Oxacilin 0.5 ug/mi Susceptible Trimethoprim + Sulfamethoxazole <=0.5/9.5 u. Susceptible | | | | | Staphylo | |
| Okacilin 0.5 ug/ml Susceptible Trimethoprim + Sulfamethoxazole <==0.5/9.5 u Susceptible | | | | Susceptible 1 | 0.25 ug/ml | Clindamycin |
| Trimethoprim + Sulfamethoxazole <v0.5 9.5="" susceptible<="" td="" u=""><td></td><td></td><td></td><td>Resistant</td><td>>4 ug/mi</td><td>Erythromycin</td></v0.5> | | | | Resistant | >4 ug/mi | Erythromycin |
| | | | | Susceptible | 0.5 ug/ml | |
| ****This is an appended report. These results have been appended to a previously preliminary verified report.*** | | | | Susceptible | < =0.5/9.5 u | Trimethoprim + Sulfamethoxazole |
| Specimen Collected: 23/12/23 9:52 Last Resulted: 26/12/23 20:27 | | | | | | ***This is an appended report. |
| | and the Street Oracle State | Dorder Details View Encounter X Lab and Collection Details | | | | |
| Ap Groer Details 14 Shew Encounter 14 Lab and Con | View All Conversations on this Encounter | | | | | |

| Status Final result Visible to patienti No (Inaccessible in MyChart). Nent appt None. Dx: ESRD on hemodialysis Specimen Information: Blood, Peripheral O Result Notes Culture beatief -> Resultella omithinolytica file i 12,111 Nore Sectore Status Statu | |
|--|--------------------------------|
| 0 Result Notes Culture Indeted → Resulted omithinolytics Industre Rossing States III + 12.11 divers Second States III + 12.11 divers Industre Rossing Gram States III - Industre Rossing III - Industre Rossing Susceptibility Resulted and therebic Blood Culture Rossing Susceptibility Susceptible Celtacolin <=2 ug/ml Susceptible Susceptibility Susceptible Susceptibility Susceptible Susceptibility Susceptible Susceptibility Susceptible | |
| Culture | |
| Gram Stain Inclusive section in the section of the | |
| Inclusion of electronic and Ascubic Blood Culture Bottline Gram Stain Susceptibility Raoutella omithinolytica MIC Ampicilin 16 ug/ml Resistant Celazolin 4-2 ug/ml Susceptible Ciprofloxacin Cipr | |
| Gram Stain Susceptibility Ampicilin Getazolin Cetazolin Cetaz | |
| Gram Stain Susceptibility Raoultella omithinolytica Mic Ampicilin T6 ug/ml Resistant. Cefazolin <i2 <="" <i2="" ciprofloxacin="" ml="" susceptible="" td="" ug=""><td></td></i2> | |
| Susceptibility | |
| Susceptibility | |
| Susceptibility Raoutella omithinolytica Ampicillin 16 ug/ml Ampicillin 16 ug/ml Cefazolin <=2 ug/ml | |
| Raoultella omithinolytica MiC Ampicilin T6 ug/ml Resistant Cefazolin <=2 ug/ml Ciprofloxacin <=2 ug/ml Gentamicin <=2 ug/ml Tobramycin <=2 ug/ml Susceptible Susceptible | |
| Mic Ampicilin Té ug/ml Resistant Cétazolin <=2 ug/ml | |
| Ampicilin T6 ug/mi Resistant Cefazolin <=2 ug/mi | |
| Ciprofloxacin <=0.125 ug/ml | |
| Gentamicin <=2 ug/ml | |
| Tobramyoin <=2 ug/mi Susceptible | |
| | |
| Trimethoprim + Sulfamethoxazole x+0.5/9.5 u Succeptible | |
| | |
| | |
| Specimien Collected: 11/09/23 14:48 Last Resulted: 14/09/23 11:58 | |
| D Order Details V View Encounter V Lab and Collection Details 14 Routing 9 R | Result History - Result Edited |
| View All Corv | wersations on this Encounter |
| Basult Fare Fogutiontion | |
| | |
| | |
| | |
| | |


Sensitivity: SAUR vs MRSA

Staphylococcus aureus

| Antimicrobial | MIC | Interpretation | Antimicrobial | MIC | Interpretation |
|--------------------------------------|---------|----------------|-----------------------------------|---------|----------------|
| Cefonitin Sereen | NBO | | Erythonysia | <+0.25 | 5 |
| Benzylpenicilin | -0.5 | Ř.: | Clindanycia | ~~0.25 | 8 |
| American | 0 | | Quinapristin Dalfopristin | <*0.25 | 5 |
| Oxacillin | 0.5 | 8 | Linexulid | 2 | s |
| Genandicki High Lood Genangy) | | | Vancemycin | -0+0.5 | 8 |
| Stroptomycin High Lavel (synergy) | | | Toracycline | -size [| 8 |
| Gertamisin | ~0.5 | 5. | Tigreycline | <=-0.12 | 8 |
| Ciprofloxacia | <=0.5 | S | Nitrofurgatoin | 32 | 5 |
| Levofloxacie. | <= 0.12 | 5 | Rifampicin | ~~ 0.5 | 5 |
| Monificancin | <= 0.25 | 5 | Trimethoprim/ Sultamethosazole | 10 | \$ |
| Inducible Clindartycin Resistance | NEG | 12 | | | |

| Antimicrobial | MIC | Interpretation | Antimicrobial | MIC | Interpretation |
|---|--------|----------------|-----------------------------------|--------|----------------|
| Cettusitie Screen | POS | ÷ | Erythromysin | ~ 0.25 | s |
| Beroylpericitlia | >= 0.5 | JL JL | Clindentychy | 348 | R |
| Ampleine | | | Quinopristin/Dalfopriatin | 0.5 | 5 |
| Oxacillin | >< 4 | R | Linerolid | 2 | 8 |
| (non-section tright pairs) (synargy) | | | Vanornycla | 2=32 | R |
| Streptomyzin High Lavel (synwygy) | 1 | | Torscyaline | >= 16 | R |
| Gentanicla | -0.5 | 5 | Tigovycline | :0.5 | S |
| Ciprofissacia | 4+0.5 | 5 | Nitrofurantois | ~ 16 | 8 |
| Levellosacin | ~ 0.12 | 8 | Rithmpicin | 1 | 8 |
| Modiflucatin | ~0.25 | 8 | Trincthiprin/ Sulfamethoscosle | <= 10 | 8 |
| Inducible Clindanyzin Resistance | NEG | 1.1 | | | |








Global Top 10 Organisms Causing

| Rank | Pathogen | All-cause age-standardised mortality rate |
|------|--------------------------|---|
| 1 | Staphylococcus aureus | 14.6 |
| 2 | E. coli | 12.6 |
| 3 | Streptococcus pneumoniae | 11.4 |
| 4 | Klebsiella pneumoniae | 11.4 |
| 5 | Pseudomonas aeruginosa | 7.4 |
| 6 | Acinetobacter baumannii | 5.8 |
| 7 | Enterobacter species | 4.2 |
| 8 | Group B Streptococcus | 4.4 |
| 9 | Enterococcus faecalis | 2.8 |
| 10 | Enterococcus faecium | 2.8 |
| 27 | Clostridioides difficile | 0.4 |

Prevalent Organisms in Healthcare

Top 15 Healthcare Associated Infection (HAI) Pathogens Reported to the National Healthcare Safety Network, Adults 2018-2021




| Pathogen | # Pathogens | % Pathogens | Ran |
|--|-----------------------|-------------|-----|
| Escherichia coli | 73 <mark>,5</mark> 56 | 16.2 | 1 |
| Staphylococcus aureus | 51,131 | 11.3 | 2 |
| Enterococcus faecalis ² | 39,129 | 8.6 | 3 |
| Select Klebsiella spp. | 38,496 | 8.5 | 4 |
| Pseudomonas aeruginosa | 36,004 | 7.9 | 5 |
| Coagulase-negative staphylococci | 32,276 | 7.1 | 6 |
| Enterobacter spp. | 18,43 <mark>1</mark> | 4.1 | 7 |
| Enterococcus faecium ² | 16,904 | 3.7 | 8 |
| Candida albicans ² | 16,458 | 3.6 | 9 |
| Proteus spp. | 13,953 | 3.1 | 10 |
| <i>Bacteroides</i> spp. | 11,602 | 2.6 | 11 |
| Viridans group streptococci | 9,962 | 2.2 | 12 |
| Other <i>Candida</i> spp. ² | 9,803 | 2.2 | 13 |
| Other Enterococcus spp. ² | 9,091 | 2.0 | 14 |
| Candida glabrata ² | 7,622 | 1.7 | 15 |
| Other pathogen | 68,522 | 15.1 | |
| Total | 452,940 | 100.0 | |

https://www.cdc.gov/nhsn/hai-report/data-tables-adult/table-3.html

CDC: Diseases and Organisms in Healthcare

| Influenza |
|---|
| Klebsiella |
| Methicillin-resistant Staphylococcus aureus (MRSA) |
| Nontuberculous Mycobacteria (NTM) |
| Norovirus |
| Pseudomonas aeruginosa |
| Staphylococcus aureus |
| Tuberculosis (TB) |
| Vancomycin-intermediate Staphylococcus aureus and Vancomycin-resistant Staphylococcus aureus |
| Vancomycin-resistant Enterococci (VRE) |
| |



Antimicrobial Resistant Bacteria & Fungi

18 Antimicrobial-Resistant Bacteria and Fungi

Threat Estimates

The following table summarizes the latest national death and infection estimates for 18 antimicrobial-resistant bacteria and fungi. The pathogens are listed in three categories—urgent, serious, and concerning—based on level of concern to human health identified in 2019.

| | Resistant Holmogen | 2017 Threat Estimate | 2018 Threat Estimate | 2019 Threat Estimate | 2017-2019 Change | 2020 Threat Estimate and 2019-2020 Change |
|--------|---|-------------------------------------|---|-------------------------------------|---------------------|--|
| | Carbapenem-resistant Acinetobacter | 8,500 cases 700 deaths | 6,300 cases 500 deaths | 6,000 cases 500 deaths | Stable* | 7,500 cases 700 deaths Overall: 35% increase* Hospital-onset: 78% increase* |
| | Antifungal-resistant <i>Candida auris</i> | 171 clinical cases! | 329 dinical cases | 466 clinical cases | Increase | 754 cases Overall: 60% increase |
| ONCENT | Clastridioides difficile | 223,900 infections 12,800 deaths | 221,200 infections 12,600 deaths | 202,600 infections 11,500 deaths | Decrease | Data delayed due to COVID-19 pandemic |
| 5 | Carbapenem-resistant Encodes textes | 13,100 cases 1,100 deaths | 10,300 <mark>cases</mark> 900 deaths | 11,900 cases 1,000 deaths | Decrease* | 12,700 cases 1,100 deaths Overall: Stable* Hospital-onset: 35% increase* |
| | Drug-resistant Neisseria gonorrhoeae | 550,000 infections | 804,000 infections | 942,000 infections | Increase | Data unavailable due to COVID-19 pandemic |
| | Drug-resi <mark>sta</mark> nt <i>Campylobacter</i> | 448,400 infections 70 deaths | 630,810 infections | 725,210 infections | Increase | Data delayed due to COVID-19 pandemic 26% of infections were resistant, a 10% decrease |
| | Antifunga Fresistant Candida | 34,800 cases 1,700 deaths | 27,000 cases 1,300 deaths | 26,600 cases 1,300 deaths | Decrease* | 28300 cases 1,400 deaths Overall: 12% increase* Hospital-onset: 26% increase* |
| | ESBL-producing Enterobacterales | 197,400 cases 9,100 deaths | 174,100 cases 8,100 deaths | 194,400 cases 9,000 deaths | Increase* | 197,500 cases 9,300 deaths Overall: 10% increase* Hospital-onset: 32% increase* |
| | Vancomy cin-resistant Enterococcus | 54,500 cases 5,400 deaths | 46,800 cases 4,700 deaths | 47,000 cases 4,700 deaths | Stable* | 50,300 cases 5,000 deaths Overall: 16% increase* Hospital-onset: 14% increase* |

COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022

SHE

https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf

15





Effect of Disinfectants on Microorganisms

| Organism | Туре | Examples |
|-----------------------------|----------|---|
| Bacterial Spores | Spore | Bacillus anthracis, Clostridioides difficile |
| Mycobacteria | Bacteria | M. tuberculosis |
| Small non-enveloped virus | Virus | Norovirus, Rhinovirus, HAV |
| Fungal spores | Fungus | Aspergillus, Penicillium, Trichophyton |
| Gram negative bacteria | Bacteria | <i>E. coli</i> , Klebsiella including CRE, Pseudomonas, Acinetobacter |
| Fungi (Vegetative) | Fungus | Candida |
| Large Virus (non-enveloped) | Virus | Adenovirus, Rotavirus |
| Gram positive bacteria | Bacteria | Staphylococcus including MRSA Enterococcus including VRE |
| Virus (enveloped) | Virus | HIV, HBV, HCV, Influenza, Coronavirus |



Adapted from Rutala et al. ICHE 2014;35(7):862

<u>S</u>*



Pesticide Registration

List P: Antimicrobial Products Registered with EPA for Claims Against Candida Auris

On this page:

- · Products on List P.
- · How to use List P products affectively
- · How to check if a produit is on List F
- Additional Resources





List K: Antimicrobial Products Registered with EPA for Claims Against Clostridium difficile Spores

On this page:


- Products on List #
- Hancht ann Lint Kurzüharts effectionie
- Haw, to meet the provident Matchers
- Herein sherik Kemedastin an Lintik
- Additional Resources



https://www.cdc.gov/hai/organisms/organisms.html

Role of the Lab During Outbreak Investigation


- Assist in the identification of an outbreak by confirming organism identities, recognizing organism clusters, detecting unusual organisms and reviewing antimicrobial susceptibility patterns.
- Retrieve and review archival data to determine background rates of organism isolation and help determine if an outbreak situation actually exists.
- Save certain microbes isolated to assist in testing to determine if the microbes are the same or related.
- IP should work closely with the laboratory team, especially when planning for a potential outbreak.
- May be part of an interdisciplinary outbreak response team



https://www.simonandschuster.ca/books/Outbreak!/Beth-Skwarecki/9781440596278



Changing Dynamics of Infectious Diseases





Emerging (EID) and Re-Emerging (REID) Infectious Diseases

EIDs are:

Outbreaks of previously unknown diseases

Known disease that is rapidly increasing in incidence or geographic area in the last 2 decades

Persistence of infectious diseases that cannot be controlled

REIDs are:

Diseases that reappear after they have been on a significant decline Re-emergence may happen because of a breakdown in public health measures for diseases that were once under control Can also happen when new strains of known disease-causing organisms appear Human behavior can affect re-emergence such as the return of vaccine preventable diseases. As a result of immunization declines, the global community is at risk for a resurgence in vaccine-preventable infections including measles, pertussis, and polio-all highly contagious diseases that result in significant morbidity and mortality in children. Most EIDs and REIDs have a zoonotic origin, denoting that the disease has emerged from an animal and crossed the species barrier to infect humans

> Factors that precipitate the occurrence and transmission of EIDs and REIDs . . .



OUR RISK FOR INFECTIOUS DISEASES

Is Increasing Because of Climate Change

- These are just some of the infectious diseases that are on the rise and spreading to new areas of the United States.
- Milder winters, warmer summers, and fewer days of frost make it easier for these and other infectious diseases to expand into new geographic areas and infect more people.



As the climate changes, the risk also increases for health threats such as:

- Anaplasmosis
- Anthrax
- Antibiotic-resistant infections
- Cryptosporidiosis
- Dengue
- Ehrlichiosis
- Fungal diseases like valley fever and histoplasmosis
- Giardiasis
- Hantavirus
- Harmful algal bloom-associated illness
- Lyme disease
- Plague
- Rabies
- Spotted fever rickettsiosis
- Salmonellosis
- Vibriosis
- West Nile virus disease

Recent Examples

Ongoing avian influenza outbreaks in animals pose risk to humans

Situation analysis and advice to countries from FAO, WHO, WOAH

G349-2822 | Submark | ServiceForte (Reading Streck mill (742 words)

The summinus sufficients of mean offserior shifts called "britthe"; have increased deviationers in ordered populations, including pockey, with briefs, and same manning, and have reflected briefs builtwords and the food make. Although simple affecting annuals, these outlenable poor organizing this to functions.

The fixed and Approxime expensions and the United Nations (MAC), the World recent Organization (WHO), and the World Organization for Arenal Health (WAV), and urging coordinates to work support account of Sets as many anomalia as possible and to purpose provide

Avain to future a strategy entrolly spread a serving forch, for the interviewing studies of HIMPL avails eVicunita interviewing analysis and a strategy strategy strategy and the strategy strategy is a strategy of the strategy strategy and some might adapt to obtain futures interviewing strategy is adapted by strategy and strategy and strategy and interviewing strategy and interviewing strategy and interviewing and strategy and between the strategy and strategy

Highly Pathogenic Avian Influenza A(H5N1) Virus: Identification of Human Infection and Recommendations for Investigations and Response

Print



Distributed via the CDC Health Alert Network April 05, 2024, 01:30 PM ET CDCHAN-00506



Severe Vibrio vulnificus Infections in the United States Associated with Warming Coastal Waters



Distributed via the CDC Health Alert Network September 01, 2023,12:30 PM ET CDCHAN-00497

Summary

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to:

- Notify healthcare providers, laboratories, and public health departments about recent reports of fatal Wbrio substitus (V. substitus) infections, including wound and foodborne infections.
- Urge healthcare professionals to consider V, vulnificut as a possible cause of infected wounds that were exposed to coastal waters, particularly near the Gulf of Mexico or East Coast, and during periods with <u>warmer coastal sea nurface</u> temperatures [2].
- · Share important guidance for managing V. subilicus wound infections.

Important Updates on Locally Acquired Malaria Cases Identified in Florida, Texas, and Maryland



Distributed via the CDC Health Alert Network August 28, 2023, 2:15 PM ET CDCHAM-00496

Summary

The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Nerwork 0.444) Health Update to share new information with clinicians, public health authorities, and the public about foculty acquired maturia costs identified in the United Status. On Applie 118, 2023, a single case of foculty acquired maturia was reported in <u>NatyGaral C3</u> in the National Capital Region. This case was caused by the Plasmostium SkiCparum? If SkiCparum? Endowshows process and is unrelated to the cases involving local transmission of Plasmostium Wave (Plasmostium Florida and Tesce described in the <u>Hall Plasmostium</u> Adviced (Plasmostium) and the cases involving local transmission of Plasmostium Wave (Plasmostium SkiCparum). There are described in the <u>Hall Plasmostium</u> Adviced (Plasmostium View) and the transmission of Plasmostium Adviced (Plasmostium) and Tesce described in the <u>Hall Plasmostium</u> identified one cases of locally acquired Plasmostium Adviced (Plasmostium) and there are also described in the <u>Hall Plasmostium</u> identified one cases are an update to that report to day. For the new deven cases and Tesce has identified one cases are also more than the 2021.

Summary





Provided an overview of different types of microorganisms



Reviewed characteristics of major groups of microorganisms along with information on identification susceptibility testing






Provided examples of laboratory reports an IP may see how to interpret and reviewed how the LAB and IP can work together



Reviewed HAIs and potential future threats to human health- emerging and re-emerging diseases

RESOURCES



Benefits:

Easy to ready & search in a table format.

Inexpensive!

Downside: Last updated in 2018, doesn't include current threats (SARS CoV-2, *Candida auris*

Examples of Significant Bacterial Toxins

| BACTERIA | TOXIN(S) | EFFECTS | |
|-----------------------------|--|---|--|
| Chatridian botalisian | bendimum nosin | Interferet with neuromatcular transmission, causing dynomia (aucommRable mascle contractions). | |
| Christidians difficile | totin A: emprotosin taxin II: cytmoxin | Mucosal inflarmation, cell/tissic damage, and pseudomembrane formation, which can lead to ulcars in the mucosa of the colors. | |
| Cherridium tetani | tetanopantin | Interferes with netwe conduction at the neuromascalar junction, causing continuous muscle commission/quants, | |
| Corynebasterium diphtheriae | diphtheria roain | Toxic to myscardial cells, the respiratory system, nerves, and kidneys. | |
| Escherichise coli | Shiga tonin | Multifacturial involvement between the organism and the host. Colonizes the gas, woulding in diarrha- and Immedial Inform, Reaction of tissues with toxics results in an inflammatory response. Toxics can alwayse kidneys. | |

Digital PDF only \$29 for APIC Members

https://secure.apic.org/web/apic/EStore/store.aspx

RESOURCES



The Infection Preventionist's

Guide to the Lab

Edited by Patricia A. Kulich, RN, CIC David L. Taylor, PhD, D(ABMM) Foreword Preface Acknowledgments

Chapter 1: Specimen Collection and Transport Chapter 2: Culture and Gram Stains Chapter 3: Blood Cultures Chapter 4: Microbial Immunology Chapter 5: Antimicrobial Testing Chapter 5: Antimicrobial Testing Chapter 6: Urinalysis, Fluid Analysis, Chemistry, and Hematology Chapter 7: Mycobacteriology Chapter 7: Mycobacteriology Chapter 8: Mycology Chapter 9: Parasitology Chapter 10: Virology Chapter 11: Other Microbiology Contributions Glossary of Abbreviations

Table 1-1: Specimen Selection, Collection, and Transport by Body Site

taper Respiratory Triest Laboratora Test Type Adventages/ Secondar. Specimen Preduency interpreta-Simple Test Hickolas cidualitizon itensbo stegory walks and year's in the second rariale priorit 10.00 m de and ti-frame) -----distant and so is -Column course March 2 Summer vision (**) and date of in the second work balders (abustance) contribute and interthe initial alline . 12 to at news inerol. complete: and start in the start of ingest interest willi Calineers · Chier at allies rafes ar 100.001 PUB indicates to minister which ATTACTOR and the second second menter. ----magint + 121 deire d ALET. AURS-A Marinini, distantiation with properties have been ----PERMIT · Rendal in sectors. 4.04 arbitle. in the second distantie . Approximation of the second in also - 11energian i State Income and a lateral st

My experience: Provides very technical info that isn't necessarily



Digital PDF only \$49 for APIC Members

https://secure.apic.org/web/apic/EStore/store.aspx

I APIC

*Published in 2012

RESOURCES



Home > Education & Certification > Course Catalog

EPI® Education Series: Basic Microbiology for Infection Preventionists

₽

Learn the fundamentals of microbiology to foster the relationship between you and your facility's micro lab.

https://apic.org/course/basic-microbiology-for-infection-preventionists/

Our Team





Vydia Nankoosingh MLT, CIC Senior Clinical Advisor

Rebecca Battjes MPH, CIC, FAPIC Senior Clinical Advisor

vnankoosingh@solenis. <u>com</u> 905-391-8337 rbattjes@solenis.com 803-280-1742



Thanks! Questions?



CREDITS: This presentation template was created by <u>Slidesgo</u>, and includes icons by <u>Flaticon</u> and infographics & images by <u>Freepik</u>



(Additional references on individual slides)

Centers for Disease Control and Prevention, HAI Pathogens and Antimicribial Resistance Report, 2018-1021 https://www.cdc.gov/nhsn/hai-report/data-tables-adult/table-3.html

Dingle, T, et. al. MALDITOF Mass Spectrometry for Microorganism Identification. Clinics in Laboratory Medicine 2013;33(3):589-609

GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-2248. doi: 10.1016/S0140-6736(22)02185-7. Epub 2022 Nov 21. PMID: 36423648; PMCID: PMC9763654.

McDonnell G, Burke P. Disinfection: is it time to reconsider Spaulding? J Hosp Infect. 2011 Jul;78(3):163-70. doi: 10.1016/j.jhin.2011.05.002. PMID: 21664533. Mora, C, et. al. Over half of known human pathogenic diseases can be aggravated by climate change. Nat. Clim. Chang. 12, 869–875 (2022). <u>https://doi.org/10.1038/s41558-022-01426-1</u>

World Health Organization, Openwho.org, Basic Microbiology Course https://openwho.org/courses/IPC-MICRO-EN/items/7raDDBfSdfeZS93tghAZFu

